Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 36,000 shares of Opko Health stock on the open market in a transaction that occurred on Friday, July 25th. The stock was purchased at an average price of $9.01 per share, for a total transaction of $324,360.00. Following the purchase, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $17,907,375. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on OPK. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, June 25th. They now have a $11.00 price target on the stock, down previously from $11.50. Separately, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Opko Health has a consensus rating of “Buy” and an average target price of $12.13.

Shares of Opko Health (NYSE:OPK) traded down 1.67% during mid-day trading on Monday, hitting $8.85. The stock had a trading volume of 827,907 shares. Opko Health has a 52 week low of $7.32 and a 52 week high of $12.95. The stock’s 50-day moving average is $8.95 and its 200-day moving average is $8.76. The company’s market cap is $3.662 billion. Opko Health also was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 48,981,522 shares, a decline of 5.6% from the June 13th total of 51,904,149 shares. Approximately 22.8% of the shares of the company are short sold. Based on an average daily volume of 3,771,645 shares, the days-to-cover ratio is currently 13.0 days.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. On average, analysts predict that Opko Health will post $-0.37 earnings per share for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.